Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

We Have Rapidly Evolved into a Company Focused on Rare Disease Medicines 2013: Net sales of $74 Million 2 Medicines DUEXIS (ibuprofen and famotidine) Tablets 800 mg/26.6 mg HORIZON 2019: Net sales of $1.3 Billion Diversified Portfolio; 6 for Rare Diseases RAVICTI (glycerol phenylbutyrate) Oral Liquid RAYOS® (Prednisone) Delayed-release Tablets KRYSTEXXA! pegloticase 12-HOUR PROCYSBI (cysteamine bitartrate) delayed-release capsules ACTIMMUNE (Interferon gamma-1b) BUPHENYL® (sodium phenylbutyrate) Quinsair aerosolized form of levofloxacin Non-Rare Disease Medicines 35

View entire presentation